<DOC>
	<DOCNO>NCT00405353</DOCNO>
	<brief_summary>Since men less likely develop multiple sclerosis , hypothesis testosterone might protective MS. Men MS follow untreated 6 month , follow 12 month treatment period Androgel .</brief_summary>
	<brief_title>Testosterone Treatment Multiple Sclerosis</brief_title>
	<detailed_description>While testosterone ( T ) previously show safe well tolerate hypogonadal male , previously give male MS patient . This study determine whether treatment testosterone ( T ) , percutaneous gel , safe well tolerate male patient relapse MS follow approach . Patients follow clinically serological study 6 month prior treatment establish baseline data . Then , testosterone ( T ) gel administer daily 100 mg per day 6 month . Patients continue follow clinically serological study . Toxic effect T gel treatment become evident patient change treatment compare baseline . To determine T gel treatment induces decrease MS disease activity , sensitive measure use , number volume gadolinium enhance lesion volume T2 lesions serial cerebral magnetic resonance imaging ( MRI ) . 12 patient undergo MRI month , 6 consecutive month , start treatment establish baseline level disease activity MRI . Then 12 patient treat T gel 6 month . Patients continue undergo serial MRI month , 6 consecutive month , treatment . In manner , level disease activity treatment compare level disease activity treatment . Patients also follow standard neurological exam ( every 3 month ) , however hypothesize , 6 month treatment , effect T gel treatment observe clinical disease activity ( disability , relapse rate ) since less sensitive measure . Further , determine whether T gel treatment induces desire effect immune system , immune response assess treatment treatment . Results vivo ( delay type hypersensitivity ) vitro ( cytokine production ) responses compare treatment treatment . Finally , since T gel therapy dose 100 mg/day show improve sexual function mood , increase lean body mass strength , decrease body fat increase bone mineral density , monitor whether positive effect also occur men MS treatment .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Men , age 1865 , diagnosis clinically definite relapse remit multiple sclerosis . 2 . Relapsing remit patient decline tolerated treatment beta interferon ( Betaseron , Avonex ) glatiramer acetate , copolymer1 ( Copaxone ) . 3 . At least one relapse two year prior entry . Relapse define historically definite worsen previous symptom ( 03 day ) development new symptom ( 03 day ) . 4 . Not intercurrent relapse . 5 . Expanded Disability Status Score ( EDSS ) = 0.0 5.0 . 6 . The patient must significant T2 burden disease screen cerebral MRI define T2 lesion load great 7.5cm3 . 7 . Must live within 100 mile UCLA . 8 . Must willing able receive initial screen cerebral MRI , baseline MRI monthly cerebral MRIs ( without gadolinium ) total period 12 month ( 6 month prior treatment 6 month treatment ) . 1 . Males unable fulfill criterion female patient . 2 . Males sex hormone treatment include androgen , estrogen , antiestrogens hypogonadism medical condition 12 month prior study . 3 . Males take DHEA 3 month prior study . 4 . Patients thrombosis , serious cardiac , pulmonary , renal , gastrointestinal , hepatic , immunologic , infectious , neoplastic ( particular focus patient know suspected estrogen testosteronedependent tumor ) , urologic disease ( particular focus patient history prostatic hypertrophy/nodules ) . 5 . Patients abnormal prostate evidence prostatic mass induration rectal examination prostate ultrasonography elevate level prostatic specific antigen ( PSA 4 ng/ml high ) . 6 . Patients testicular mass exam . 7 . Patients hematocrit great 50 % 8 . Patients major psychiatric illness ( e.g . manic depressive state , schizophrenia ) 9 . Patients active alcoholism . 10 . Patients history drug abuse within past five year . 11 . Patients great 130 % le 80 % ideal body weight base Metropolitan Life Tables . 12 . Patients generalized skin disease may effect absorption testosterone ( e.g . psoriasis ) know skin intolerance alcohol . 13 . Patients prolactin &gt; 40 mcg/L . 14 . Patients cholesterol level great 300 mg/dl . 15 . Patients condition would interfere assess neurologic function deform arthritis major amputation . 16 . Patients receive treatment beta interferon ( Betaseron Avonex ) , glatiramer acetate copolymer1 ( Copaxone ) , ACTH , corticosteroid , intravenous immunoglobulin ( IVIG ) , plasma exchange three month precede enrollment 17 . Patients receive treatment azathioprine , cyclophosphamide , methotrexate , mitoxantrone , cyclosporin A experimental therapy six month precede enrollment . 18 . Patients treat total lymphoid irradiation , monoclonal antibody , T cell vaccination , cladribine bone marrow transplantation . 19 . Patients positive titer HIV1,2 ; HTLV1 ; VDRL . 20 . Patients clinical evidence Lyme disease . 21 . Patients mentally emotionally incompetent opinion examine neurologist unable give inform consent , understand comply study protocol . 22 . Patients certain artificial heart valve , pacemaker , metallic/electronic material body . 23 . Patients know hypersensitivity gadoliniumDPTA .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>multiple sclerosis</keyword>
	<keyword>testosterone</keyword>
</DOC>